Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prelude Therapeutics Inc

0.7502
+0.01021.38%
Volume:61.50K
Turnover:45.78K
Market Cap:41.29M
PE:-0.42
High:0.7680
Open:0.7456
Low:0.7020
Close:0.7400
Loading ...

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

GlobeNewswire
·
27 Nov 2024

Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health

TIPRANKS
·
26 Nov 2024

Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)

Zacks
·
11 Nov 2024

Prelude Therapeutics (PRLD) Receives a Sell from Barclays

TIPRANKS
·
08 Nov 2024

Prelude Therapeutics (PRLD) Gets a Sell from Morgan Stanley

TIPRANKS
·
07 Nov 2024

Prelude Therapeutics: Promising Developments and Strategic Collaborations Drive Buy Rating

TIPRANKS
·
07 Nov 2024

Prelude Therapeutics Q3 EPS $(0.43) Beats $(0.47) Estimate

Benzinga
·
07 Nov 2024

BRIEF-Prelude Therapeutics Q3 EPS USD -0.43

Reuters
·
07 Nov 2024

Prelude Therapeutics Inc: Current Cash Runway Into 2026

THOMSON REUTERS
·
07 Nov 2024

Prelude Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
28 Oct 2024

Optimism in Prelude Therapeutics: Buy Rating Backed by Promising PRT3789 Trial Results

TIPRANKS
·
28 Oct 2024

Prelude Therapeutics price target lowered to $1 from $3 at Barclays

TIPRANKS
·
27 Oct 2024

Prelude Therapeutics: Sell Rating Due to Limited Efficacy Improvement and Financial Challenges

TIPRANKS
·
26 Oct 2024

Buy Rating Affirmed for Prelude Therapeutics Amid Positive Developments in PRT3789 and Strong Financial Position

TIPRANKS
·
25 Oct 2024

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

GlobeNewswire
·
24 Oct 2024

Prelude announces publication of abstracts on SMARCA Degrader Programs

TIPRANKS
·
09 Oct 2024